Prostate Cell News Volume 6.04 | Feb 6 2015

    0
    26
    Prostate Cell News 6.04 February 6, 2015

    Prostate Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  PCN on Twitter

     
    TOP STORY
    Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
    Researchers developed enzalutamide resistant prostate cancer cells in an effort to understand the mechanisms of resistance. Global gene expression analysis showed that steroid biosynthesis pathway is activated in enzalutamide resistant prostate cancer cells. [Cancer Res] Abstract
    ProstaCultâ„¢: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide Resistant Prostate Cancer Cell Growth
    To define functional roles of androgen receptor (AR) full length (ARFL) and AR-variants (AR-Vs) in enzalutamide-resistant (ENZ-R) castration resistant prostate cancer (CRPC), scientists designed three antisense oligonucleotides targeting exon-1, intron-1, and exon-8 in AR pre-mRNA to knockdown ARFL alone or with AR-Vs, and examined their effects in three CRPC cell lines and patient-derived xenografts. [Clin Cancer Res] Abstract

    Novel C-4 Heteroaryl 13-Cis Retinamide Mnk/AR Degrading Agents Inhibit Cell Proliferation and Migration and Induce Apoptosis in Human Breast and Prostate Cancer Cells and Suppress Growth of MDA-MB-231 Human Breast and CWR22Rv1 Human Prostate Tumor Xenografts in Mice
    The authors discuss the synthesis and in vitro and in vivo anti-breast and anti-prostate cancers activities of novel C-4 heteroaryl 13-cis retinamides that modulate Mnk-eIF4E and AR signaling. [J Med Chem] Abstract

    In PC3 Prostate Cancer Cells Ephrin Receptors Crosstalk to β1-Integrins to Strengthen Adhesion to Collagen Type I
    Researchers examined how ephrin-A1 stimulates PC3 cells to adhere to extracellular matrix proteins using single-cell force spectroscopy. They found that PC3 cells binding to immobilized ephrin-A1 but not to solubilized ephrin-A1 specifically strengthen adhesion to collagen I. [Sci Rep] Full Article

    The Hippo Pathway Effector, YAP, Regulates Motility, Invasion and Castration-Resistant Growth of Prostate Cancer Cells
    Researchers show that enhanced expression of Yes-associated protein (YAP) was able to transform immortalized prostate epithelial cells and promoted migration and invasion in both immortalized and cancerous prostate cells. [Mol Cell Biol] Abstract

    Reciprocal Regulation of GAS5 lncRNA Levels and mTOR Inhibitor Action in Prostate Cancer Cells
    The effects of mTOR inhibitors on growth-arrest specific 5 (GAS5) lncRNA levels and cell growth were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. [Prostate] Abstract

    Tumor-Suppressive MicroRNA-145 Induces Growth Arrest by Targeting SENP1 in Human Prostate Cancer Cells
    Scientists found that the low expression of microRNA-145 (miR-145) was correlated with the high expression of small ubiquitin-like modifier-specific protease 1 (SENP1) in prostate cancer cell line PC-3. The transient introduction of miR-145 caused cell cycle arrest in PC-3 cells, and the opposite effect can be observed when miR-145 inhibitor was transfected. [Cancer Sci] Abstract

    The Upregulation of PI3K/Akt and MAP Kinase Pathways Is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer
    The PI3K/Akt and MAP kinase pathways were investigated utilizing paclitaxel resistant DU145-TxR prostate cancer cells and their parental non-resistant DU145 cells to determine their relationship with resistance to paclitaxel and other anticancer drugs. [J Cell Biochem] Abstract

    CH5137291, an Androgen Receptor Nuclear Translocation-Inhibiting Compound, Inhibits the Growth of Castration-Resistant Prostate Cancer Cells
    Researchers developed an androgen receptor (AR) pure antagonist, CH5137291, with AR nuclear translocation-inhibiting activity, and compared its activity and characteristics with that of bicalutamide. Cell lines corresponding to the mechanisms of castration resistance were used: LNCaP-BC2 having AR overexpression and LNCaP-CS10 having androgen-independent AR activation. [Int J Oncol] Abstract

    CLINICAL RESEARCH

    A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer
    The authors explored the feasibility and efficacy of docetaxel plus prednisone for Chinese population with metastatic castration refractory prostate cancer. [PLoS One] Full Article

    PCA3 in Prostate Cancer and Tumor Aggressiveness Detection on 407 High-Risk Patients: A National Cancer Institute experience
    The early diagnosis relies on prostate specific antigen (PSA) serum test, even if it showed clear limits. Among the new tests currently under study, one of the most promising is the prostate cancer gene 3 (PCA3), a non-coding mRNA whose level increases up to 100 times in prostate cancer tissues when compared to normal tissues. The authors contribute to the validation of the clinical utility of the PCA3 test and to the evaluation of its prognostic potential. [J Exp Clin Cancer Res] Abstract | Full Article

    [Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.

     
    REVIEWS
    Leading Causes of Castration-Resistant Prostate Cancer
    The authors summarize the widely accepted mechanisms that account for castration-resistant prostate cancer and discuss potential therapeutic targets. [Expert Rev Anticancer Ther] Abstract

    Visit our reviews page to see a complete list of reviews in the prostate cell research field.

     
    INDUSTRY NEWS
    Jefferson Joins Elite Prostate Cancer Clinical Trials Consortium (PCCTC)
    The Sidney Kimmel Cancer Center at Thomas Jefferson University was appointed membership to the PCCTC, joining 14 other leading academic medical centers in the nation’s premier prostate cancer clinical trials group. [Jefferson University Hospitals] Press Release

    Cord Blood Registry Announces Formation of Scientific & Medical Advisory Board
    Cord Blood Registry® (CBR®) announced the establishment of a Scientific and Medical Advisory Board (SMAB). Composed of internationally renowned stem cell experts, the SMAB will provide input and guidance to help advance CBR’s mission to expand the scope of newborn stem cell therapies that may be available to patients and their families. [Cord Blood Registry®] Press Release

    From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Advanced Prostate Cancer Consensus Conference
    March 12-14, 2015
    St. Gallen, Switzerland

    Visit our events page to see a complete list of events in the prostate cell community.

     
    JOB OPPORTUNITIES
    NEW Director – Vector Production (Sangamo BioSciences, Inc.)

    NEW Senior Process Development Engineer (Sangamo BioSciences, Inc.)

    NEW Postdoctoral Research – Scientist Metabolic Adaptation in Treatment Resistant Prostate Cancer (Cancer Research UK Beatson Institute in Glasgow)

    Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

    Postdoctoral Researcher – Prostate Cancer (Spanish National Cancer Research Centre [CNIO])

    Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

    Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

    Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

    PhD Studentship – Chemokine Receptor in Prostate Cancer Metastasis (University of East Anglia)

    Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Prostate Cell News: Archives | Events | Contact Us